Cell Processing and Storage Core

细胞处理和存储核心

• 批准号: 7240145
• 负责人: Shelly Heimfeld
• 金额: $ 69.93万
• 依托单位: FRED HUTCHINSON CANCER RESEARCH CENTER
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2011-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7240145
• 关键词: Aliquot; Allogenic; Applications Grants; Blood donor; Bone Marrow; Cell Lineage; Cell physiology; Cells; Clinical; Cyclic GMP; DNA; Data; Dendritic Cells; Development; Disease; Engineering; Engraftment; Flow Cytometry; Funding; Future; Generations; Grant; Hematopoietic; Homologous Transplantation; Immune; Individual; Lymphoid; Malignant - descriptor; Outcome; PRTN3 gene; Patient Care; Patients; Peripheral Blood Stem Cell; Preparation; Process; Production; Public Health; Research Personnel; Sampling; Services; Specimen; T-Lymphocyte; Technical Expertise; Techniques; Third-Party Payer; Transplant Recipients; Transplantation; WT1 gene; Work; cost; disorder control; graft vs host disease; improved; instrumentation; novel; reconstitution; repository; response; success; tumor

Core E: Cell Processing and Storage will support this grant proposal by providing four specific functions. First, this core will provide critical instrumentation and technical expertise in cell procurement and processing of all clinical components necessary to support the treatment of patients with malignant diseases described in Projects 1-6. Direct funding is not requested for most of that activity, which is generally reimbursed by third party payers, but Core E will also procure and distribute research specimens and provide additional summary data to investigators. Second, the Core will characterize the bone marrow and PBSC components utilized in these allogeneic transplantation studies by quantitative flow cytometry for various T-cell and other lymphoid subsets. These data will be useful in determining which specific cell lineages may be correlated with clinical outcomes, which will in turn help to stimulate the development of novel graft engineering approaches and techniques that could improve future allogeneic transplantation studies. Third, Core E will operate a Repository of Research Specimens. This Repository will consist of two distinct types of components: (1) aliquots of patient and normal donor blood and/or bone marrow samples; (2) DNA preparations and established B-LCL lines obtained from allogeneic transplant patients and their corresponding normal donors. These samples will be critical in helping to define the mechanisms involved in engraftment, rejection, anti-tumor response and disease control, immune reconstitution, and the development of graft-versus-host disease. Material from this Repository will support studies outlined in Projects 1 , 2, 5, and 6. Fourth, Core E will be responsible for the development and clinical implementation of cell processing techniques necessary for the cGMP production of the WT1 and PR3 T-cells described in Project 5, and for the depletion of naive T-cells and subsequent generation of primed donor dendritic-cells described in Project 6. Integration of the clinical cell processing services of Core E with the projects contained within this grant application provides for better patient care, a higher degree of QA/QC, and significantly reduced efforts and costs. Relevance to public health: The support of Core E is critical to the success of the work proposed in the individual projects of this grant. This work promises to advance the field of allogeneic hematopoietic transplantation, making it safer, more effective, increasingly available and more appropriately applied. Such an advance could have obvious relevance to the thousands of patients who are transplanted each year or are potential candidates for transplantation.

核心 E：细胞处理和存储将通过提供四个特定功能来支持这项拨款提案。 首先，该核心将提供细胞采购和处理方面的关键仪器和技术专业知识 描述了支持治疗恶性疾病患者所需的所有临床成分 在项目 1-6 中。大多数活动不需要直接资助，通常由 第三方付款人，但 Core E 还将采购和分发研究样本，并提供额外的 向调查人员提供汇总数据。其次，核心将表征骨髓和 PBSC 成分 通过定量流式细胞术在这些同种异体移植研究中使用各种 T 细胞和其他细胞 淋巴亚群。这些数据将有助于确定哪些特定细胞谱系可能相关 具有临床效果，这反过来将有助于刺激新型移植工程的发展 可以改善未来同种异体移植研究的方法和技术。三、Core E将 运营研究样本库。该存储库将包含两种不同类型的 成分：（1）患者和正常供体血液和/或骨髓样本的等分试样； (2)DNA 从同种异体移植患者及其患者身上获得的制剂和已建立的 B-LCL 系 相应的正常捐献者。这些样本对于帮助定义涉及的机制至关重要 植入、排斥、抗肿瘤反应和疾病控制、免疫重建以及 移植物抗宿主病的发展。该存储库中的材料将支持中概述的研究 项目1、2、5、6。四、Core E将负责开发和临床实施 WT1 和 PR3 T 细胞的 cGMP 生产所需的细胞处理技术 项目 5，用于消耗初始 T 细胞并随后生成引发的供体树突状细胞 项目 6 中描述。Core E 的临床细胞处理服务与所包含项目的集成 在此拨款申请中提供了更好的患者护理、更高程度的 QA/QC 以及显着 减少工作量和成本。 与公共卫生的相关性：核心 E 的支持对于《报告》中提出的工作的成功至关重要 这笔补助金的个别项目。这项工作有望推动同种异体造血领域的发展 移植，使其更安全、更有效、越来越容易获得和更适当地应用。这样的 这一进步可能与每年接受移植的数千名患者有明显的相关性，或者 是潜在的移植候选者。